Literature DB >> 16198088

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.

Donald C Goff1, Lisa M Sullivan, Joseph P McEvoy, Jonathan M Meyer, Henry A Nasrallah, Gail L Daumit, Steven Lamberti, Ralph B D'Agostino, Thomas S Stroup, Sonia Davis, Jeffrey A Lieberman.   

Abstract

OBJECTIVE: Standardized mortality rates are elevated in schizophrenia compared to the general population. The incidence of coronary heart disease (CHD) and the relative contribution of CHD to increased mortality in schizophrenia patients are not clear, despite recent concerns about metabolic complications of certain atypical antipsychotics.
METHOD: Ten-year risk for CHD was calculated for 689 subjects who participated in the Clinical Trials of Antipsychotic Treatment Effectiveness (CATIE) Schizophrenia Trial at baseline using the Framingham CHD risk function and were compared with age-, race- and gender-matched controls from the National Health and Nutrition Examination Survey (NHANES) III.
RESULTS: Ten-year CHD risk was significantly elevated in male (9.4% vs. 7.0%) and female (6.3% vs. 4.2%) schizophrenia patients compared to controls (p = 0.0001). Schizophrenia patients had significantly higher rates of smoking (68% vs. 35%), diabetes (13% vs. 3%), and hypertension (27% vs. 17%) and lower HDL cholesterol levels (43.7 vs. 49.3 mg/dl) compared to controls (p < 0.001). Only total cholesterol levels did not differ between groups. Ten-year CHD risk remained significantly elevated in schizophrenia patients after controlling for body mass index (p = 0.0001).
CONCLUSIONS: These results are consistent with recent evidence of increased cardiac mortality in schizophrenia patients. While the impact of cigarette smoking is clear, the relative contributions to cardiac risk of specific antipsychotic agents, diet, exercise, and quality of medical care remain to be clarified.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16198088     DOI: 10.1016/j.schres.2005.08.010

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  142 in total

1.  Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness.

Authors:  Joseph C Ratliff; Laura B Palmese; Erin L Reutenauer; Vinod H Srihari; Cenk Tek
Journal:  Psychosomatics       Date:  2012-06-02       Impact factor: 2.386

2.  Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.

Authors:  Marc De Hert; Dan Cohen; Julio Bobes; Marcelo Cetkovich-Bakmas; Stefan Leucht; David M Ndetei; John W Newcomer; Richard Uwakwe; Itsuo Asai; Hans-Jurgen Möller; Shiv Gautam; Johan Detraux; Christoph U Correll
Journal:  World Psychiatry       Date:  2011-06       Impact factor: 49.548

3.  A case control study of the implementation of change model versus passive dissemination of practice guidelines for compliance in monitoring for metabolic syndrome.

Authors:  Dawn I Velligan; Desiree Castillo; Linda Lopez; Bren Manaugh; Charlotte Davis; Juanita Rodriguez; A Camis Milam; Albana Dassori; Alexander L Miller
Journal:  Community Ment Health J       Date:  2012-02-16

4.  Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey.

Authors:  Jaana Suvisaari; Jonna Perälä; Samuli I Saarni; Tommi Härkänen; Sami Pirkola; Matti Joukamaa; Seppo Koskinen; Jouko Lönnqvist; Antti Reunanen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04       Impact factor: 5.270

5.  Feasibility and effectiveness of an automated telehealth intervention to improve illness self-management in people with serious psychiatric and medical disorders.

Authors:  Sarah I Pratt; Stephen J Bartels; Kim T Mueser; John A Naslund; Rosemarie Wolfe; Heather S Pixley; Louis Josephson
Journal:  Psychiatr Rehabil J       Date:  2013-12

6.  Diabetes is associated with lower global cognitive function in schizophrenia.

Authors:  Yoichiro Takayanagi; Nicola G Cascella; Akira Sawa; William W Eaton
Journal:  Schizophr Res       Date:  2012-09-29       Impact factor: 4.939

7.  Psychotic symptoms are associated with physical health problems independently of a mental disorder diagnosis: results from the WHO World Health Survey.

Authors:  Carmen Moreno; Roberto Nuevo; Somnath Chatterji; Emese Verdes; Celso Arango; José Luis Ayuso-Mateos
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

Review 8.  Tobacco use among individuals with schizophrenia: what role has the tobacco industry played?

Authors:  Judith J Prochaska; Sharon M Hall; Lisa A Bero
Journal:  Schizophr Bull       Date:  2007-11-05       Impact factor: 9.306

9.  [Mental disorders and diabetes mellitus].

Authors:  Heidemarie Abrahamian; Alexandra Kautzky-Willer; Angelika Rießland-Seifert; Peter Fasching; Christoph Ebenbichler; Peter Hofmann; Hermann Toplak
Journal:  Wien Klin Wochenschr       Date:  2012-12       Impact factor: 1.704

10.  Cigarette smoking and mortality risk in people with schizophrenia.

Authors:  Deanna L Kelly; Robert P McMahon; Heidi J Wehring; Fang Liu; Kristen M Mackowick; Douglas L Boggs; Kimberly R Warren; Stephanie Feldman; Joo-Cheol Shim; Raymond C Love; Lisa Dixon
Journal:  Schizophr Bull       Date:  2009-12-17       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.